StockAxis

Hikal Ltd

Quarterly Result - Q1YFY23

Hikal Ltd

Pharmaceuticals & Drugs - Global

Current

CMP
Rs. 257
Rating:
Hold
August 10, 2022

Previous

Rating:
Hold

Stock Info

BSE
524735
NSE
HIKAL
Bloomberg
HKCL:IN
Reuters
HIKA.NS
Sector
Pharmaceuticals & Drugs - Global
Face Value (Rs)
2
Equity Capital (Rs cr)
25
Mkt Cap (Rs cr)
3328.50
52w H/L (Rs)
742.00 - 212.00
Avg Daily Vol (BSE+NSE)
555,299

Shareholding Pattern

(as on 30-Jun)
%
Promoter
68.77
FIIs
3.91
DIIs
0.89
Public & Others
26.43
Source: Ace equity, StockAxis Research

Price performance

Return (%)
1m
3m
12m
Absolute
8.65
-34.98
-56.08
Sensex
8.13
8.19
7.81
Source: Ace equity, StockAxis Research

Indexed Stock Performance

Hikal Ltd Sensex
Hikal Ltd
Source: Ace equity, StockAxis Research

Financial Highlights:

Particulars (Rs. in Crores) Q1FY23 Q1FY22 YoY Q4FY22 QoQ
Revenue from Operations 378.79 456.78 -17.10% 502.35 -24.60%
EBITDA 22.75 95.76 -76.20% 60.99 -62.70%
EBITDA Margin (%) 6.00% 21.00% 12.10%
Profit After Tax -8.86 50.54 -117.50% 20.71 -142.80%
Net Profit Margin (%) -2.30% 11.10% 4.10%
Earnings Per Share -0.72 4.10 -117.60% 1.68 -142.90%

Source: Company Filings; StockAxis Research

Highlights for the Quarter Ended June 2022
During the quarter ended June 2022, Hikal posted weak set of numbers, which was largely expected mainly due to the closure of Taloja plant, which contributes ~15% to the topline (FY22). However, the plant is fully operational now and we can expect it to restart contributing from Q2FY22 onwards. Also, the company, during the quarter faced margin pressure on account of higher input costs. However, the management said that the prices have started easing out and a positive impact on margins is expected to be visible in the coming quarters.

The revenue for the quarter was ~Rs. 379 crores, a de-growth of -17.1% YoY and -24.6% QoQ. The crop protection business was impacted due to the closure of Taloja plant. The good part is that the company used the closure period to undertake annual preventive maintenance. The pharmaceuticals segment also witnessed a de-growth of ~18% YoY and ~27% QoQ on the back of temporary demand softening of key products and channel inventory correction by customers.

EBITDA for the quarter was Rs. 23 crores, a decline of 76.2% YoY and 62.7% QoQ and margin also witnessed a contraction by 1,496bps YoY and 613 bps QoQ primarily due to lower sales and product mix, increase in cost of raw materials, energy, and solvents. Further, under absorption of fixed costs during the quarter also reduced the EBITDA. The company bottom line was also impacted. During the Q1FY23, Hikal posted loss of Rs. 8.9 crores vs. profit of Rs. 50.5 crores and Rs. 20.7 crores in Q1FY22 and Q4FY22, respectively.

Key Conference Call Highlights

  • The management indicated that there would be sequential improvement in the business over the next three quarters. The management is witnessing price softening of key raw materials and expects this trend to continue in the following months. The reduction in prices of raw material could partly benefit in quarter Q2FY22 and majority benefit should accrue from H2FY23 onwards.
  • Pharma Segment
    • The Pharma business EBIT was negative Rs. 8 crores, which is attributed to lower sales, increase in input costs coupled with lag in passing the increased cost, and lower absorption of fixed costs. However, the company’s business excellence initiatives resulted in cost reduction, which partially aided absorbing the impact of higher input costs.
    • The segment added several new customers and strengthened presence in new geographies of LatAm and Middle East.
    • With the softening of raw material and solvent prices, the company expects sales and profitability to improve in upcoming quarters.
    • It has ~10 products in the pipeline at various stages and plans to launch 3-4 products in FY23.
    • FY23 will be a year of consolidation where the company would rebuild the business despite market pressure and likely to deliver better results in H2FY23.
  • Crop Protection
    • The EBIT of the segment was Rs. 10 crores in Q1FY23, primarily on the back of lower sales, higher input cost, solvents, energy as well as lower absorption of fixed costs.
    • The management is witnessing rising inquiries from existing as well as new customers for potential collaborations.
    • Construction of new multipurpose plant is on track at Panoli and expects to commission it in H1FY23. At peak utilization, the management expects revenue of Rs. 300 crores, which could be achieved in FY26.
    • Getting good traction of new fungicides in the pipeline from customers. In a process of strengthening the presence in Europe and Latin America.
    • Continue to explore new product opportunities in the segment. Presently, working on 5-6 products at different stages of development.
    • Taloja operations has resumed, efforts are focused towards covering the production loss of Q1FY23 to best extent over the next 3 quarters.
  • The business has not lost a single customer or contract in any of the segments during this period. Pressure in Q1 was expected to be high, but management is confident of achieving an improvement in profitability QoQ, starting Q2.
  • The business does not expect to post lower sales than FY22 of Rs. 1,900 crores and for FY24 and FY25, the management targets high teens growth with higher growth in FY25.
  • Margins could improve by 50-100bps vs FY22 margins from next fiscal. FY23 is not considered as it is the year of consolidation.
  • Investing Rs. 300-400 crores every year. The incremental capex’s asset turn is 1.5x.
  • In the next 5 years, the company would endeavour to catch up and the level of top 2-3 competitors. The idea is to grow and accelerate growth in the next 3-5 years significantly.

Outlook & valuation

We believe the company will continue to benefit from its established track record, healthy pipeline of generic APIs, introduction of new products, along with favourable growth prospects for the existing products. It has a healthy pipeline of products under development for proprietary and contract manufacturing, which is expected to support its growth prospects, especially in the export market. The company is in the process to do capex of ~Rs. 600 crores, of which Rs. 273 crores was done in FY22. By FY24/FY25, the business could reach peak utilization which is expected to aid revenue growth.

At CMP of ~Rs. 257, the stock trades at ~11x of FY25E earnings.

Quarterly Financials

Particulars (Rs. in Crores) Q1FY23 Q1FY22 YoY Q4FY22 QoQ
Revenue from Operations 378.79 456.78 -17.10% 502.35 -24.60%
COGS 226.38 224.91 277.57
Gross Profit 152.41 231.87 224.78
Gross Profit Margin (%) 40.20% 50.80% 44.70%
Employee Benefit Expenses 43.21 48.09 53.62
Other Expenses 86.45 88.02 110.17
EBITDA 22.75 95.76 -76.20% 60.99 -62.70%
EBITDA Margin (%) 6.00% 21.00% 12.10%
Depreciation & Amortisation 26.50 22.56 24.23
EBIT -3.75 73.20 -105.10% 36.76 -110.20%
EBIT Margin (%) -1.00% 16.00% 7.30%
Finance Cost 11.29 7.99 8.08
Other Income 3.27 3.18 0.27
Profit Before Tax -11.77 68.39 -117.20% 28.95 -140.70%
Tax Expenses -2.91 17.85 8.24
Effective Tax Rate (%) 24.70% 26.10% 28.50%
Profit After Tax -8.86 50.54 -117.50% 20.71 -142.80%
Net Profit Margin (%) -2.30% 11.10% 4.10%
Earnings Per Share -0.72 4.10 -117.60% 1.68 -142.90%

Source: Company Filings; StockAxis Research

Consolidated Financial statements

Profit & Loss statement

Year End March (Rs. in Crores) 2021 2022 2023E 2024E 2025E
Net Sales 1720.44 1942.72 1954.00 2281.50 2691.11
Growth % 14.14% 12.92% 0.58% 16.76% 17.95%
Expenditure
Material Cost 908.38 996.39 1041.25 1192.96 1380.23
Employee Cost 164.32 203.38 212.99 223.59 242.20
Other Expenses 324.86 402.39 382.32 428.14 505.01
EBITDA 322.89 340.56 317.44 436.81 563.67
EBITDA Margin 18.77% 17.53% 16.25% 19.15% 20.95%
Depreciation & Amortization 85.25 95.67 116.29 134.53 149.73
EBIT 237.64 244.89 201.15 302.28 420.96
EBIT Margin % 13.81% 12.61% 10.29% 13.25% 15.64%
Other Income 4.98 4.89 5.13 6.11 7.01
Interest & Finance Charges 36.20 31.21 36.09 36.48 32.85
Profit Before Tax 206.43 218.57 170.19 271.92 388.11
Tax Expense 73.29 58.06 42.89 68.52 97.80
Effective Tax rate 35.50% 26.56% 25.20% 25.20% 25.20%
Consolidated Net Profit 133.14 160.51 127.30 203.40 290.31
Net Profit Margin after MI 7.74% 8.26% 6.51% 8.91% 10.79%

Balance Sheet

As of March (Rs. in Crores) 2021 2022 2023E 2024E 2025E
Share Capital 24.66 24.66 24.66 24.66 24.66
Total Reserves 908.74 1043.32 1157.89 1338.91 1594.38
Shareholders' Funds 933.40 1067.98 1182.55 1363.57 1619.04
Non Current Liabilities
Long Term Borrowing 262.89 286.68 351.75 301.75 236.75
Current Liabilities
Short Term Borrowings 251.43 387.76 387.76 387.76 387.76
Trade Payables 229.62 249.06 256.22 232.08 258.85
Total Equity & Liabilities 2015.70 2213.12 2399.91 2506.79 2724.03
Assets
Net Block 712.55 879.47 1043.18 1108.65 1158.93
Current Assets
Inventories 266.70 328.98 330.95 342.32 398.49
Sundry Debtors 485.53 437.72 427.04 458.36 551.76
Cash and Bank 36.81 49.09 80.88 79.60 97.00
Total Assets 2015.70 2213.12 2399.91 2506.79 2724.03

Cash Flow Statement

Year End March (Rs. in Crores) 2021 2022 2023E 2024E 2025E
Profit After Tax 133.14 160.51 127.30 203.40 290.31
Depreciation 85.25 95.67 116.29 134.53 149.73
Changes in Working Capital -57.89 18.69 15.87 -66.83 -122.80
Cash From Operating Activities 229.02 293.73 259.46 271.09 317.24
Purchase of Fixed Assets -157.60 -273.31 -280.00 -200.00 -200.00
Free Cash Flows 71.42 20.42 -20.54 71.09 117.24
Cash Flow from Investing Activities 71.42 20.42 -20.54 71.09 117.24
Increase / (Decrease) in Loan Funds -32.95 66.75 65.07 -50.00 -65.00
Equity Dividend Paid -14.82 -27.13 -12.73 -22.37 -34.84
Cash from Financing Activities -96.87 -5.56 52.34 -72.37 -99.84
Net Cash Inflow / Outflow -24.05 3.80 31.80 -1.28 17.40
Opening Cash & Cash Equivalents 31.68 7.64 11.44 43.24 41.95
Closing Cash & Cash Equivalent 7.64 11.44 43.24 41.95 59.35

Key Ratios

Year End March 2021 2022 2023E 2024E 2025E
Basic EPS 10.80 13.02 10.32 16.50 23.54
DPS 2.00 1.60 1.03 1.81 2.83
Book value (Rs/share) 75.70 86.62 95.91 110.59 131.31
ROCE (%) Post Tax 17.18% 15.66% 11.26% 15.52% 19.59%
ROE (%) 14.26% 15.03% 10.76% 15.98% 19.47%
PE 13.29 30.90 24.93 15.60 10.93
P/BV 1.90 4.64 2.68 2.33 1.96
EV/EBITDA 7.25 16.51 12.19 8.64 6.55
Dividend Yield (%) 1.39% 0.40% 0.40% 0.71% 1.10%
P/Sales 1.03 2.55 1.62 1.39 1.18
Net debt/Equity 0.61 0.62 0.59 0.44 0.32
Net Debt/ EBITDA 1.77 1.95 2.19 1.37 0.92
Sales/Net FA (x) 2.38 2.44 2.03 2.12 2.37